Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Amyris Declines Following Downgrade From Raymond James

Feb. 12 (Bloomberg) -- Amyris Inc., the biotechnology company part-owned by Total SA, dropped after a downgrade by Raymond James & Associates Inc.

Amyris fell 8.1 percent to $3.52 at the close in New York. Earlier, it declined as much as 12 percent, the most intraday since Aug. 1.

The company’s discounted-cash flow multiple recently reached 111 percent, the highest level among its peers, Pavel Molchanov, a Raymond James analyst in Houston, said in a report today.

“This was purely a tactical, valuation-based downgrade,” Molchanov said today in an interview. “The fundamentals of the company have not changed in the last month or two months.”

Molchanov lowered Amyris to underperform, the equivalent of a sell. Amyris is the only underperform-rated stock among the alternative-fuels companies that Raymond James covers, according to the report.

Amyris uses genetically modified microorganisms to convert plant-sugars into farnesene, a hydrocarbon that can be processed into fuels or specialty chemicals.

Total, France’s largest oil producer, owns 18 percent of Emeryville, California-based Amyris, according to data compiled by Bloomberg.

To contact the reporter on this story: Justin Doom in New York at jdoom1@bloomberg.net

To contact the editor responsible for this story: Reed Landberg at landberg@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.